logo

Centre of Evidence of Dermatology Best practice guidelines

Guidelines hidradenitis suppurativa Updated on august 2019

Responsibility


The information provided by this website comes from sources deemed reliable. However, the French Dermatology Society recommends that the user ensure the validity of this information. Some may prove to be erroneous or be subject to typos or display errors.

The use of this data is under the sole responsibility of the user. The French Dermatology Society cannot be blamed for a misinterpretation of the data provided by the site, or in the event of erroneous information. This decision tree and all the contents of this site have been developed in the context of updated data from science according to the HAS methodology, expert opinions and reviewers of the various documents and in the context of the French healthcare system.


Follicular forms
Relapse

Back to decision-making tree Print last updated on 07/04/2020

In case of second-line treatment failure

  • Adalimumab 160/80/40 mg/week [D]

OR

  • Infliximab 5 mg/kg every 6-8 weeks [E]

→ revaluation at 6 months

read immunosuppressive treatments


A
In cases of treatment failure, intolerance or contraindication for cyclins antibiotics (risk of serious toxidermia)
B
Medical and surgical concertation meeting specifically on HS
C
Double dose if weight > 80 kg
D
MA, but not reimbursed
E
No MA
  • Was this article helpful to you?
  • Your opinion counts!

    This notice will not be published on this site, but only sent to the publication management. Your email will only be used to reply to you if we deem it necessary. No response will be sent to any request for medical advice via this form.


back to decision-making tree

Centre of Evidence of Dermatology Centre of Evidence of Dermatology logo
Work
10 cité Malesherbes
75009Paris
Île-de-France
FRANCE
Work +33.1 43 27 01 56
Fax +33.1 43 27 01 86
centredepreuvesdermato@sfdermato.org